SCHEMBL6323637

SCHEMBL6323637

Cc1ccsc1-c1noc(N)c1C(=O)NCc1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
CHRM4 P08173 1/20 0.46
POLB P06746 3/20 0.46
ADORA2A P29274 2/20 0.44
ADORA2B P29275 2/20 0.44
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA1 P30542 1/20 0.41
THRB P10828 1/20 0.40
TP53 P04637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAOB P27338 1/20 0.39
EPHX2 P34913 1/20 0.39
GAA P10253 1/20 0.39
SCD O00767 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316125 0.90 POLB (0.47) ALDH1A1HPGDPOLBADORA2AADORA2B
SCHEMBL6318890 0.89 ADORA1 (0.44) ALDH1A1HPGDPOLBADORA2AADORA2B
SCHEMBL6318418 0.88 POLB (0.53) LMNAALDH1A1POLBMAPK1RAB9A
SCHEMBL6322463 0.88 NPC1 (0.46) LMNAHPGDPOLBRAB9AKMT2A
SCHEMBL6318410 0.87 POLB (0.42) LMNAALDH1A1CHRM4POLBKMT2A
SCHEMBL6315404 0.84 KMT2A (0.47) LMNAALDH1A1HPGDPOLBMAPK1
SCHEMBL6316645 0.83 TACR1 (0.44) POLBMAOB
SCHEMBL6322200 0.82 POLB (0.47) LMNAALDH1A1HPGDCHRM4POLB
SCHEMBL6316383 0.82 CHRM4 (0.48) LMNAALDH1A1HPGDCHRM4POLB
SCHEMBL6324517 0.82 NAMPT (0.47) LMNAALDH1A1POLBKMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 LMNA 3334/4885ALDH1A1 4444/4885HPGD 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.